Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival

(2012) T. L. Lasho et al.   BLOOD

Mutation analysis ofASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12,andTET2in myeloproliferative neoplasms

(2012) Mandy Brecqueville et al.   GENES CHROMOSOMES & CANCER

Polyclonal Immunoglobulin Free Light Chain Levels Predict Survival in Myeloid Neoplasms

(2012) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-Platelet Therapy and Aspirin Resistance – Clinically and Chemically Relevant?

(2011) M. Rafferty et al.   CURRENT MEDICINAL CHEMISTRY

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

(2011) O Abdel-Wahab et al.   LEUKEMIA

p53 Lesions in Leukemic Transformation

(2011) Ashot Harutyunyan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis

(2010) F. Passamonti et al.   BLOOD

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

(2010) A Tefferi et al.   LEUKEMIA

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

(2010) D Caramazza et al.   LEUKEMIA

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

LNKMutations inJAK2Mutation–Negative Erythrocytosis

(2010) Terra L. Lasho et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcome of Transplantation for Myelofibrosis

(2009) Karen K. Ballen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis

(2009) K. Hussein et al.   BLOOD

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

(2009) P. Guglielmelli et al.   BLOOD

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2009) N. Kroger et al.   BLOOD

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

(2009) Jocelin Huang et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Conventional cytogenetics in myelofibrosis: literature review and discussion

(2009) Kebede Hussein et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

(2009) Constantine S. Tam et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

(2009) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

(2009) A Tefferi et al.   LEUKEMIA

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

(2009) A Tefferi et al.   LEUKEMIA

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Risk factors for leukemic transformation in patients with primary myelofibrosis

(2008) Jocelin Huang et al.   CANCER

Refining the Selection Criteria for Laparoscopic Versus Open Splenectomy for Splenomegaly

(2008) Liane S. Feldman et al.   Journal of Laparoendoscopic & Advanced Surgical Techniques

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA